Know Clascoterone and how it could fight Androgenetic Alopecia

Hair loss is a problem that affects millions of people worldwide. Although there are some treatments currently available, none represent a definitive cure. However, there are some drugs that are in advanced clinical trials and could represent a solution to the problem of hair loss.

Hair loss affects millions around the world, but a ray of hope shines through recent developments. Meet Clascoterone, a potential game-changer in the fight against Androgenetic Alopecia (AGA). Although still in clinical trials, Clascoterone shows immense potential in the treatment of hair loss, possibly surpassing existing treatments like minoxidil.

Unlocking the future:

Clascoterone [CB-03-01] is a topical medication initially designed for the treatment of acne. This molecule is a potent androgen receptor inhibitor, so its potential to combat androgenetic alopecia is being tested.

Androgenetic alopecia is characterized by an increased effect of testosterone on androgen receptors in dermal papilla cells. By blocking these receptors, testosterone will not have a negative effect on follicle cells, preventing miniaturization and hair loss.

Outlining the path ahead:

As phase III trials begin, Clascoterone has significant potential to revolutionize the treatment of hair loss. These trials aim to evaluate its efficiency and safety in the treatment of AGA, a common but challenging condition that affects millions worldwide. If approved by the FDA, Clascoterone would be the first effective topical drug found against androgenetic alopecia in nearly three decades!

While the path to fight hair loss is ongoing, the progress of Clascoterone is a beacon of hope. At CapilarFix®, we remain vigilant, combining science and experience to transform lives affected by hair loss.

Schedule your consultation today!

References:

Dhillon S. Clascoterone: First Approval. Drugs. 2020 Nov;80(16):1745-1750. doi: 10.1007/s40265-020-01417-6. PMID: 33030710.
H. Y. Sun, D. F. Sebaratnam, Clascoterone as a novel treatment for androgenetic alopecia, Clinical and Experimental Dermatology, Volume 45, Issue 7, 1 October 2020, Pages 913–914, https://doi.org/10.1111/ced.14292